60 Degrees Pharmaceuticals Seeks FDA Clearance for Australian Chestnut Extract Supplement
Event summary
- 60 Degrees Pharmaceuticals filed a New Dietary Ingredient Notification (NDIN) with the FDA for Australian Chestnut Extract on March 11, 2026.
- FDA has until May 25, 2026, to object to the notification.
- The company signed an option agreement with Florida State University to license a capsule formulation for the extract.
- This follows the company's January 2026 exercise of a license option for large-scale production of castanospermine.
The big picture
60 Degrees Pharmaceuticals is diversifying its portfolio beyond vector-borne disease treatments by entering the dietary supplement market. The strategic shift aligns with broader industry trends of pharmaceutical companies exploring complementary health products. The company's collaboration with Florida State University underscores its commitment to leveraging academic research for commercial applications.
What we're watching
- Regulatory Timeline
- Whether the FDA will object to the NDIN by the May 25, 2026 deadline, which would allow the company to market its dietary supplement.
- Product Viability
- How the company will leverage the safety record of castanospermine from previous clinical trials to support its marketing efforts.
- Strategic Expansion
- The pace at which the company can scale production and commercialize the Australian Chestnut Extract supplement following FDA clearance.
Related topics